Adam, JA, Menheere, PP, van Dielen, FM, Soeters, PB, Buurman, WA & Greve, JW (2002) Decreased plasma orexin-A levels in obese individuals. Int J Obes Relat Metab Disord 26, 274–276.
Adami, GF, Meneghelli, A & Scopinaro, N (1999) Night eating and binge-eating disorder in obese patients. Int J Eat Disord 25, 335–338.
Asakawa, A, Inui, A, Kaga, T, Yuzuriha, H, Nagata, T, Fujimiya, M, Katsuura, G, Makino, S, Fujino, MA & Kasuga, M (2001) A role of ghrelin in neuroendocrine and behavioral responses to stress in mice. Neuroendocrinology 74, 143–147.
Ballinger, A, McLoughlin, L, Medback, S & Clark, M (1995) Cholecystokinin is a satiety hormone in humans at physiological concentrations. Clin Sci 89, 375–381.
Batterham, RL (2002) Gut hormone PYY3-36 physiologically inhibits food intake. Nature 418, 650–654.
Batterham, RL, Cohen, MA, Ellis, SM, Le Roux, CW, Withers, DJ, Frost, GS, Ghatei, MA & Bloom, SR (2003) Inhibition of food intake in obese subjects by peptide YY3-36. N Engl J Med 349, 941–948.
Batterham, RL, Cowley, MA, Small, CJ, et al. (2002) Gut hormone PYY(3-36) physiologically inhibits food intake. Nature 418, 650–654.
Bell, GI, Santerre, RF & Mullenbach, GT (1983) Hamster preproglucagon contains the sequence of glucagon and two related peptides. Nature 302, 716–718.
Berg, AH, Combs, TP & Scherer, PE (2002) ACRP30/adiponectin: an adipokine regulating glucose and lipid metabolism. Trends Endocrinol Metab 13, 84–89.
Bloom, SR (1997) Glucagon-like peptide-1 and satiety. Nature 385, 214.
Branson, R, Potoczna, N, Kral, JG, Lentes, KU, Hoehe, MR & Horber, FF (2003) Binge eating as a major phenotype of melanocortin 4 receptor gene mutations. N Engl J Med 348, 1096–1103.
Bray, GA (2000) Afferent signals regulating food intake. Proc Nutr Soc 59, 373–384.
Broberger, C, Holmberg, K, Kuhar, MJ & Hokfelt, T (1999) Cocaine- and amphetamine-regulated transcript in the rat vagus nerve: a putative mediator of cholecystokinin-induced satiety. Proc Natl Acad Sci USA 96, 13506–13511.
Broberger, C, Johansen, J, Johansson, C, Schalling, M & Hokfelt, T (1998) The neuropeptide Y/agouti gene-related protein (AGRP) brain circuitry in normal, anorectic, and monosodium glutamate-treated mice. Proc Natl Acad Sci USA 95, 15043–15048.
Brolin, RE (1992) Critical analysis of results: weight loss and quality of data. Am J Clin Nutr 55, 577S–581S.
Buchan, AM, Polak, JM, Solcia, E, Capella, C, Hudson, D & Pearse, AG (1978) Electron immunohistochemical evidence for human intestinal I cells as the source of CCK. Gut 19, 403–407.
Burdyga, G, Lal, S, Spiller, D, et al. (2003) Localization of orexin-1 receptors to vagal afferent neurons in the rat and humans. Gastroenterology 124, 129–139.
Chamorro, S, Della-Zuana, O, Fauchere, JL, Feletou, M, Galizzi, JP & Levens, N (2002) Appetite suppression based on selective inhibition of NPY receptors. Int J Obes Relat Metab Disord 26, 281–298.
Clement, K, Dina, C, Basdevant, A, Chastang, N, Pelloux, V, Lahlou, N, Berlan, M, Langin, D, Guy-Grand, B & Froguel, P (1999) A sib-pair analysis study of 15 candidate genes in French families with morbid obesity: indication for linkage with islet 1 locus on chromosome 5q. Diabetes 48, 398–402.
Cummings, DE & Foster, KE (2003) Ghrelin–leptin tango in body-weight regulation. Gastroenterology 124, 1532–1535.
Cummings, DE, Purnell, JQ, Frayo, RS, Schmidova, K, Wisse, BE & Weigle, DS (2001) A preprandial rise in plasma ghrelin levels suggests a role in meal initiation in humans. Diabetes 50, 1714–1719.
De Zwaan, M, Mitchell, JE, Raymond, NC & Spitzer, RL (1994) Binge eating disorder: clinical features and treatment of a new diagnosis. Harv Rev Psychiatry 1, 310–325.
Flegal, KM, Carroll, MD, Ogden, CL & Johnson, CL (2002) Prevalence and trends in obesity among US adults, 1999–2000. J Am Med Assoc 288, 1723–1727.
Flint, A, Raben, A, Astrup, A & Holst, JJ (1998) Glucagon-like peptide-1 promotes satiety and suppresses energy intake in humans. J Clin Invest 101, 515–520.
Flint, A, Raben, A, Rehfeld, JF, Holst, JJ & Astrup, A (2000) The effect of glucagon-like peptide-1 on energy expenditure and substrate metabolism in humans. Int J Obes 24, 288–298.
French, SJ, Murray, B, Rumsey, RD, Sepple, CP & Read, NW (1993) Is cholecystokinin a satiety hormone? Correlations of plasma cholecystokinin with hunger, satiety and gastric emptying in normal volunteers. Appetite 21, 95–104.
Fuxe, K, Tinner, B, Caberlotto, L, Bunnemann, B & Agnati, L (1997) NPY Y1 receptor-like immunoreactivity exists in a subpopulation of β-endorphin immunoreactive nerve cells in the arcuate nucleus: a double immunolabelling analysis in the rat. Neurosci Lett 225, 49–52.
Geliebter, A (1988) Gastric distension and gastric capacity in relation to food intake in humans. Physiol Behav 44, 665–668.
Geliebter, A (2002) Weight loss and plasma ghrelin levels. N Engl J Med 347, 1379–1381.
Geliebter, A & Hashim, SA (2001) Gastric capacity in normal, obese, and bulimic women. Physiol Behav 74, 743–746.
Geliebter, A, Melton, PM, McCray, RS, Gallagher, DR, Gage, D & Hashim, SA (1992) Gastric capacity, gastric emptying, and test-meal intake in normal and bulimic women. Am J Clin Nutr 56, 656–661.
Geliebter, A, Westreich, S, Pierson, RN & Van Itallie, TB (1986) Extra-abdominal pressure alters food intake, intragastric pressure, and gastric emptying rate. Am J Physiol 250, R549–R552.
Geliebter, A, Yahav, E, Gluck, M & Hashim, SA (2004) Gastric capacity, test meal intake, and appetitive hormones in binge-eating disorder. Physiol Behav (In Press).
Geracioti, TD & Liddle, RA (1988) Impaired cholecystokinin secretion in bulimia nervosa. N Engl J Med 319, 683–688.
Grill, HJ & Norgren, R (1978) Chronically decerebrate rats demonstrate satiation but not bait-shyness. Science 201, 267–269.
Gutzwiller, JP, Drewe, J, Göke, BSchmidt, H, Rohrer, B, Lareida, J & Beglinger, C (1999a) Glucagon-like peptide-1 promotes satiety and reduces food intake in patients with diabetes mellitustype 2. Am J Physiol 276, R1541–R1544.
Gutzwiller, JP, Göke, B, Drewe, J, Hildebrand, P, Ketterer, S, Handschin, D, Winterhalder, R, Conen, D & Beglinger, C (1999b) Glucagon-like peptide-1: a potent regulator of food intake in humans. Gut 44, 81–86.
Hagan, MM (2002) PeptideYY: a key mediator of orexigenic behavior. Peptides 23, 377–382.
Hagan, MM, Rushing, PA, Pritchard, LM, Schwartz, MW, Strack, AM, Van Der Ploeg, LH, Woods, SC & Seeley, RJ (2000) Long-term orexigenic effects of AgRP-(831-32) involve mechanisms other than melanocortin receptor blockade. Am J Physiol Regul Integr Comp Physiol 279, R47–R52.
Hahn, TM, Breininger, JF, Baskin, DG & Schwartz, MW (1998) Coexpression of Agrp and NPY in fasting-activated hypothalamic neurons. Nat Neurosci 1, 271–272.
Hewson, G, Leighton, RG & Hughes, J (1988) The cholecystokinin receptor antagonist L364,718 increases food intake in the rat by attenuation of the action of endogenous cholecystokinin. Br J Pharmacol 93, 79–84.
Heymsfield, SB, Greenberg, AS, Fujioka, K, et al. (1999) Recombinant leptin for weight loss in obese and lean adults: a randomized, controlled, dose-escalation trial. J Am Med Assoc 282, 1568–1575.
Hill, JO & Peters, JC (1998) Environmental contributions to the obesity epidemic. Science 280, 1371–1374.
Holst, JJ (1997) Enteroglucagon. Annu Rev Physiol 59, 257–271.
Hotta, K, Funahashi, T & Arita, Y (2000) Plasma concentrations of a novel, adipose-specific protein, adiponectin, in type 2 diabetic patients. Arterioscler Thromb Vasc Biol 20, 1595–1599.
Hu, E, Liang, P & Spiegelman, BM (1996) AdipoQ is a novel adipose-specific gene dysregulated in obesity. J Biol Chem 271, 10697–10703.
Hug, C & Lodish, HF (2002) Diabetes, obesity, and Acrp30/adiponectin. Biotechniques 33, 654–656 658 passim.
Imeryuz, N, Yegen, BC, Bozkurt, A, Coskun, T, Villanueva-Penacarrillo, ML & Ulusoy, NB (1997) Glucagon-like peptide-1 inhibits gastric emptying via vagal afferent-mediated central mechanisms. Am J Physiol 273, G920–G927.
Jin, SL, Han, VK, Simmons, JG, Towle, AC, Lauder, JM & Lund, PK (1988) Distribution of glucagonlike peptide I (GLP-I), glucagon, and glicentin in the rat brain: an immunocytochemical study. J Comp Neurol 271, 519–532.
Kersten, S, Mandard, S, Tan, NS, Escher, P, Metzger, D, Chambon, P, Gonzalez, FJ, Desvergne, B & Wahli, W (2000) Characterization of the fasting-induced adipose factor FIAF, a novel peroxisome proliferator-activated receptor target gene. J Biol Chem 275, 28488–28493.
Kim, I, Kim, HG, Kim, H, Kim, HH, Park, SK, Uhm, CS, Lee, ZH & Koh, GY (2000) Hepatic expression, synthesis and secretion of a novel fibrinogen/angiopoietin-related protein that prevents endothelial-cell apoptosis. Biochem J, 346, 603–610.
Kirchgessner, AL (2002) Orexins in the brain–gut axis. Endocrol Rev 23, 1–15.
Kirchgessner, AL & Liu, M (1999) Orexin synthesis and response in the gut. Neuron 24, 941–951.
Kissileff, HR, Pi-Sunyer, FX, Thornton, J & Smith, GP (1981) C-terminal octapeptide of cholecystokinin decreases food intake in man. Am J Clin Nutr 34, 154–160.
Kojima, M, Hosoda, H, Date, Y, Nakazato, M, Matsuo, H & Kangawa, K (1999) Ghrelin is a growth-hormone-releasing acylated peptide from stomach. Nature 402, 656–660.
Komaki, G, Matsumoto, Y, Nishikata, H, Kawai, K, Nozaki, T, Takii, M, Sogawa, H & Kubo, C (2001) Orexin-A and leptin change inversely in fasting non-obese subjects. Eur J Endocrinol 144, 645–651.
Kreymann, B, Ghatei, MA, Burnet, P, Williams, G, Kanse, S, Diani, AR & Bloom, SR (1989) Characterization of glucagon-like peptide-1-(73-6)amide in the hypothalamus. Brain Res 502, 325–331.
Lambert, PD, Wilding, PH, Ghatei, MA & Bloom, SR (1994) A role for GLP-1-(73-6)NH2 in the central control of feeding behaviour. Digestion 54, 360–361.
Lieverse, RJ, Jansen, JBMJ, Zwan, A, Samson, L, Masclee, AAM & Lamers, CBHW (1993) Satiety effects of a physiological dose of cholecystokinin in humans. Gut 36, 176–179.
Londos, C, Gruia-Gray, J, Brasaemle, DL, Rondinone, CM, Takeda, T, Dwyer, NK, Barber, T, Kimmel, AR & Blanchette-Mackie, EJ (1996) Perilipin: possible roles in structure and metabolism of intracellular neutral lipids in adipocytes and steroidogenic cells. Int J Obes Relat Metab Disord 20, Suppl. 3S97–S101.
Long, SJ, Sutton, JA, Amaee, WB, Giouvanoudi, A, Spyrou, NM, Rogers, PJ & Morgan, LV (1999) No effect of glucagon-like peptide-1 on short-term satiety and energy intake in man. Br J Nutr 81, 273–279.
Lovshin, J & Drucker, DJ (2000) New frontiers in the biology of GLP-2. Regul Pept 90, 27–32.
Mac Dougald, OA & Mandrup, S (2002) Adipogenesis: forces that tip the scales. Trends Endocrinol Metab 13, 5–11.
Matsubara, M, Maruoka, S & Katayose, S (2002) Inverse relationship between plasma adiponectin and leptin concentrations in normal-weight and obese women. Eur J Endocrinol 147, 173–180.
Mercer, JG & Lawrence, CB (1992) Selectivity of cholecystokinin (CCK) receptor antagonists, MK-329 and L-365,260, for axonally-transported CCK binding sites on the rat vagus nerve. Neurosci Lett 137, 229–231.
Morley, JE, Levine, AS, Grace, M & Kneip, J (1985) Peptide YY, (PYY), a potent orexigenic agent. Brain Res 341, 200–203.
Nakazato, M, Murakami, N, Date, Y, Kojima, M, Matsuo, H, Kangawa, K & Matsukura, S (2001) A role for ghrelin in the central regulation of feeding. Nature 409, 194–198.
Näslund, E, Barkeling, B, King, N, Gutniak, M, Blundell, JE, Holst, JJ, Rössner, S, Hellström, PM (1999a) Energy intake and appetite are suppressed by glucagon-like peptide-1 (GLP-1) in obese men. Int J Obes Relat Metab Disord 23, 304–311.
Näslund, E, Bogefors, J, Skogar, S, Grybäck, P, Jacobsson, H, Holst, JJ, Hellström, PM (1999b) GLP-1 slows solid gastric emptying and inhibits insulin, glucagon, and PYY release in humans. Am J Physiol 277, R910–R916.
Näslund, E, Ehrström, M, Ma, J, Hellström, PM & Kirchgessner, AL (2002) Localization and effects of orexin on fasting motility in the rat duodenum. Am J Physiol 282, G470–G479.
Näslund, E, Grybäck, P, Backman, L, Jacobsson, H, Holst, JJ, Theo-dorsson, E, Hellström, PM (1998a) Distal small bowel hormones: correlation with fasting antroduodenal motility and gastric emptying. Dig Dis Sci 43, 945–952.
Näslund, E, Gutniak, M, Skogar, S, Rossner, S & Hellström, PM (1998b) Glucagon-like peptide 1 increases the period of postprandial satiety and slows gastric emptying in obese men. Am J Clin Nutr 68, 525–530.
Näslund, E, King, N, Mansten, S, Adner, S, Holst, JJ, Gutniak, M & Hellström, PM (2004) Prandial subcutaneous injuctions of glucagon-like peptide-1 cause weight loss in obsess human subjects. Br J Nutr 91, 439–446.
Nauck, MA, Niedereichholz, U, Ettler, R, Holst, JJÖrskov, CRitzel, R & Schmiegel, WH (1997) Glucagon-like peptide 1 inhibition of gastric emptying outweighs its insulinotropic effects in healthy humans. Am J Physiol 273, E981–E988.
Nowak, KW, Mackowiak, P, Switonska, MM, Fabis, M & Malendowicz, LK (2000) Acute orexin effects on insulin secretion in the rat: in vivo and in vitro studies. Life Sci 66, 449–454.
O'Rahilly, S (2003) Leptin: defining its role in humans by the clinical study of genetic disorders. Nutr Rev 60, 30–34.
Ørskov, C (1992) Glucagon-like peptide-1, a new hormone of the enteroinsular axis. Diabetologia 35, 701–711.
Otto, B, Cuntz, U, Fruehauf, E, Wawarta, R, Folwaczny, C, Riepl, RL, Heiman, ML, Lehnert, P, Fichter, M & Tschop, M (2001) Weight gain decreases elevated plasma ghrelin concentrations of patients with anorexia nervosa. Eur J Endocrinol 145, 669–673.
Ouedraogo, R, Näslund, E & Kirchgessner, AL (2003) Glucose regulates the release of orexin-a from the endocrine pancreas. Diabetes 52, 111–117.
Pajvani, UB, Du, X, Combs, TP, Berg, AH, Rajala, MW, Schulthess, T, Engel, J, Brownlee, M & Scherer, PE (2003) Structure–function studies of the adipocyte-secreted hormone Acrp30/adiponectin. Implications for metabolic regulation and bioactivity. J Biol Chem 278, 9073–9085.
Poeschla, B, Gibbs, J, Simansky, KJ, Greenberg, D & Smith, GP (1993) Cholecystokinin-induced satiety depends on activation of 5-HT1C receptors. Am J Physiol 264, R62–R64.
Porte, D, Baskin, DG & Schwartz, MW (2002) Leptin and insulin action in the central nervous system. Nutr Rev 60, S20–S29.
Ranganath, L, Norris, F, Morgan, L, Wright, J & Marks, V (1999) Inhibition of carbohydrate-mediated glucagon-like peptide-1 (73-6)amide secretion by circulating non-esterified fatty acids. Clin Sci 96, 335–342.
Ranganath, LR, Beety, JM, Morgan, LM, Wright, JW, Howland, R & Marks, V (1996) Attenuated GLP-1 secretion in obesity: cause or consequence. Gut 38, 916–919.
Raybould, HE (1998) Does your gut taste? Sensory transduction in the gastrointestinal tract. News Physiol Sci 13, 275–280.
Read, N, French, SA & Cunningham, K (1994) The role of the gut in regulating food intake in man. Nutr Rev 52, 1–10.
Reidelberger, RD, Varga, G & Solomon, TE (1991) Effects of selective cholecystokinin antagonists L364,718 and L365,260 on food intake in rats. Peptides 12, 1215–1221.
Reubi, JC, Waser, B, Laderach, U, Stettler, C, Friess, H, Halter, F & Schmassmann, A (1997) Localization of cholecystokinin A and cholecystokinin B-gastrin receptors in the human stomach. Gastroenterology 112, 1197–1205.
Ritter, RC, Covasa, M & Matson, CA (1999) Cholecystokinin: proofs and prospects for involvement in control of food intake and body weight. Neuropeptides 33, 387–399.
Sakurai, T, Amemiya, A, Ishii, M, et al. (1998) Orexins and orexin receptors: a family of hypothalamic neuropeptides and G protein-coupled receptors that regulate feeding behavior. Cell 92, 573–585.
Sanaka, M, Koike, Y, Yamamoto, T, Mineshita, S, Yamaoka, S, Hirama, S, Tanaka, H, Kuyama, Y & Yamanaka, M (1997) A reliable and convenient parameter of the rate of paracetamol absorption to measure gastric emptying rate of liquids. Int J Clin Pharmacol Ther 35, 509–513.
Sanaka, M, Kuyama, Y & Yamanaka, M (1998) Guide for judicious use of the paracetamol absorption technique in a study of gastric emptying rate of liquids. J Gastroenterol 33, 785–791.
Scherer, PE, Williams, S, Fogliano, M, Baldini, G & Lodish, HF (1995) A novel serum protein similar to C1q, produced exclusively in adipocytes. J Biol Chem 270, 26746–26749.
Schmidt, PT, Näslund, EGrybäck, PJacobsson, H, Hartmann, B, Holst, JJ, Hellström, PM (2003) Peripheral administration of GLP-2 to humans has no effect on gastric emptying or satiety. Regul Pept 116, 21–25.
Schwartz, GJ, McHugh, PR & Moran, TH (1993) Gastric loads and cholecystokinin synergistically stimulate rat gastric vagal afferents. Am J Physiol 265, R872–R876.
Shapiro, L & Scherer, PE (1998) The crystal structure of a complement-1q family protein suggests an evolutionary link to tumor necrosis factor. Curr Biol 8, 335–338.
Shiiya, T, Nakazato, M, Mizuta, M, Date, Y, Mondal, MS, Tanaka, M, Nozoe, S, Hosoda, H, Kangawa, K & Matsukura, S (2002) Plasma ghrelin levels in lean and obese humans and the effect of glucose on ghrelin secretion. J Clin Endocrinol Metab 87, 240–244.
Shimizu, I, Hirota, M, Ohboshi, C & Shima, K (1987) Identification and localization of glucagon-like peptide-1 and its receptor in rat brain. Endocrinology 121, 1076–1082.
Sobhani, I, Bado, A & Vissuzaine, C (2000) Leptin secretion and leptin receptor in the human stomach. Gut 47, 178–183.
Sobhani, I, Buyse, M, Goiot, H, Weber, N, Laigneau, JP, Henin, D, Soul, JC & Bado, A (2002) Vagal stimulation rapidly increases leptin secretion in human stomach. Gastroenterology 122, 259–263.
Sørensen, LB, Flint, A, Raben, A, Hartmann, B, Holst, JJ & Astrup, A (2003) No effect of physiological concentrations of glucagon-like peptide-2 on appetite and energy intake in normal weight subjects. Int J Obes 27, 450–456.
Stellar, E (1954) The physiology of motivation. Psychol Rev 61, 5–22.
Steppan, CM, Bailey, ST, Bhat, S, Brown, EJ, Banerjee, RR, Wright, CM, Patel, HR, Ahima, RS & Lazar, MA (2001) The hormone resistin links obesity to diabetes. Nature 409, 307–312.
Takaya, K, Ariyasu, H & Kanamoto, N (2000) Ghrelin strongly stimulates growth hormone release in humans. J Clin Endocrinol Metab 85, 4908–4911.
Tang-Christensen, M, Larsen, PJ, Göke, RFink-Jensen, A, Jessop, DS, Moller, M & Sheikh, SP (1996) Central administration of GLP-1-(7-36) amide inhibits food and water intake in rats. Am J Physiol 271, R848–R856.
Tang-Christensen, M, Larsen, PJ, Thulesen, J, Romer, J & Vrang, N (2000) The proglucagon-derived peptide, glucagon-like peptide-2, is a neurotransmitter involved in the regulation of food intake. Nat Med 6, 802–807.
Tansey, JT, Sztalryd, C, Gruia-Gray, J, et al. (2001) Perilipin ablation results in a lean mouse with aberrant adipocyte lipolysis, enhanced leptin production, and resistance to diet-induced obesity. Proc Natl Acad Sci USA 98, 6494–6499.
Toft-Nielsen, MB, Madsbad, S & Holst, JJ (1999) Continuous subcutaneous infusion of glucagon-like peptide-1 lowers plasma glucose and reduces appetite in type 2 diabetic patients. Diabetes Care 22, 1137–1143.
Tolessa, T, Gutniak, M, Holst, JJ, Efendic, S & Hellström, PM (1998) Glucagon-like peptide-1 retards gastric emptying and small bowel transit in the rat: effect mediated through central or enteric nervous mechanisms. Dig Dis Sci 43, 2284–2290.
Trayhurn, P & Beattie, JH (2001) Physiological role of adipose tissue: white adipose tissue as an endocrine and secretory organ. Proc Nutr Soc 60, 329–339.
Tsai, CH, Hill, M & Drucker, DJ (1997) Biological determinants of intestinotrophic properties of GLP-2. Am J Physiol 272, G662–G668.
Tsao, TS, Lodish, HF & Fruebis, J (2002) ACRP30, a new hormone controlling fat and glucose metabolism. Eur J Pharmacol 440, 213–221.
Tschop, M, Smiley, DL & Heiman, ML (2000) Ghrelin induces adiposity in rodents. Nature 407, 908–913.
Tschop, M, Weyer, C, Tataranni, PA, Devanarayan, V, Ravussin, E & Heiman, ML (2001) Circulating ghrelin levels are decreased in human obesity. Diabetes 50, 707–709.
Turton, MD, O'Shea, D & Gunn, I (1996) A role for glucagon-like peptide-1 in the central regulation of feeding. Nature 379, 69–72.
Ukkola, O & Santaniemi, M (2002) Adiponectin: a link between excess adiposity and associated comorbidities? J Mol Med 80, 696–702.
Wettergren, A, Schjoldager, B, Mortensen, PE, Myhre, J, Christiansen, J & Holst, JJ (1993) Truncated GLP-1 (proglucagon 781-07-amide) inhibits gastric and pancreatic functions in man. Dig Dis Sci 38, 665–673.
Wettergren, A, Wøjdemann, M & Holst, JJ (1998) Glucagon-like peptide-1 inhibits gastropancreatic function by inhibiting central parasympathetic outflow. Am J Physiol 275, G984–G992.
Wettergren, A, Wøjdemann, M, Meisner, S, Stadil, F & Holst, JJ (1997) The inhibitory effect of glucagon-like peptide-1 (GLP-1) 7-36 amide on gastric acid secretion in humans depends on an intact vagal innervation. Gut 40, 597–601.
Wikberg, JE, Muceniece, R, Mandrika, I, Prusis, P, Lindblom, J, Post, C & Skottner, A (2000) New aspects on the melanocortins and their receptors. Pharmacol Res 42, 393–420.
Wøjdemann, M, Wettergren, A, Hartmann, B & Holst, JJ (1998) Glucagon-like peptide-2 inhibits centrally induced antral motility in pigs. Scand J Gastroenterol 33, 828–832.
Wren, AM, Seal, LJ, Cohen, MA, Brynes, AE, Frost, GS, Murphy, KG, Dhillo, WS, Ghatei, MA & Bloom, SR (2001) Ghrelin enhances appetite and increases food intake in humans. J Clin Endocrinol Metab 86, 5992
Yanovski, SZ (1993) Binge eating disorder: current knowledge and future directions. Obes Res 1, 306–324.
Yanovski, SZ (1995) Biological correlates of binge-eating. Addict Behav 20, 705–712.
Yeo, GS, Farooqi, IS, Aminian, S, Halsall, DJ, Stanhope, RG & O'Rahilly, S (1998) A frameshift mutation in MC4R associated with dominantly inherited human obesity. Nat Genet 20, 111–112.
Zhang, Y, Proenca, R, Maffei, M, Barone, M, Leopold, L & Friedman, JM (1994) Positional cloning of the mouse obese gene and its human homologue. Nature 372, 425–432.